Ceregene

About:

Ceregene is a biotechnology company that treats neurodegenerative disorders using the delivery of nervous system growth factors.

Website: http://www.ceregene.com

Top Investors: Michael J. Fox Foundation, MPM Capital, Alta Partners, Cell Genesys, Investor Growth Capital Limited

Description:

Ceregene is a private, San Diego-based biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Their clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor, which is about to enter Phase 2 studies for the treatment of Alzheimer's disease, and CERE-120, which recently completed a Phase 2 trial in Parkinson's disease and is currently being evaluated for future development. CERE-135 and CERE-140 are in preclinical development for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and ocular diseases, respectively.